Metabolic syndrome, prediabetes, and brain abnormalities onmri in patients with manifest arterial disease: The smart-mr study

Audrey M. Tiehuis, Yolanda Van Der Graaf, Willem P T M Mali, Koen Vincken, Majon Muller, Mirjam I. Geerlings

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

OBJECTIVE: Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors leading to atherosclerosis and diabetes. Diabetes is associated with both structural and functional abnormalities of the brain. MetS, even before diabetes is diagnosed, may also predispose to cerebral changes, probably through shared mechanisms. We examined the association of MetS with cerebral changes in patients with manifest arterial disease. RESEARCH DESIGN AND METHODS Cross-sectional data on MetS and brain MRI were available in 1,232 participants withmanifest arterial disease (age 58.6610.1 years; 37%MetS). Volumes of brain tissue, ventricles, and white matter hyperintensities (WMH) were obtained by automated segmentation and expressed relative to intracranial volume. Infarcts were distinguished into lacunar and nonlacunar infarcts. RESULTS: The presence of MetS (n = 451) was associated with smaller brain tissue volume (B 20.72% [95% CI 20.97, 20.47]), even in the subgroup of patients without diabetes (B 20.42% [95% CI 20.71, 20.13]). MetS was not associated with an increased occurrence of WMH or cerebral infarcts. Impaired glucose metabolism, abdominal obesity, and elevated triglycerides were individual components associated with smaller brain volume. Obesity and hypertriglyceridemia remained associated with smaller brain volume when patients with diabetes were excluded. Hypertension was associated with an increased occurrence of WMH and infarcts. CONCLUSIONS: In patients with manifest arterial disease, presence of MetS is associated with smaller brain volume, even in patients without diabetes. Screening for MetS and treatment of its individual components, in particular, hyperglycemia, hypertriglyceridemia, and obesity, may prevent progression of cognitive aging in patients with MetS, even in a prediabetic stage.

Original languageEnglish
Pages (from-to)2515-2521
Number of pages7
JournalDiabetes Care
Volume37
Issue number9
DOIs
Publication statusPublished - 1 Jan 2014

Cite this

Tiehuis, Audrey M. ; Van Der Graaf, Yolanda ; Mali, Willem P T M ; Vincken, Koen ; Muller, Majon ; Geerlings, Mirjam I. / Metabolic syndrome, prediabetes, and brain abnormalities onmri in patients with manifest arterial disease : The smart-mr study. In: Diabetes Care. 2014 ; Vol. 37, No. 9. pp. 2515-2521.
@article{9f4715bd054e4d039f29ca1a96e2156b,
title = "Metabolic syndrome, prediabetes, and brain abnormalities onmri in patients with manifest arterial disease: The smart-mr study",
abstract = "OBJECTIVE: Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors leading to atherosclerosis and diabetes. Diabetes is associated with both structural and functional abnormalities of the brain. MetS, even before diabetes is diagnosed, may also predispose to cerebral changes, probably through shared mechanisms. We examined the association of MetS with cerebral changes in patients with manifest arterial disease. RESEARCH DESIGN AND METHODS Cross-sectional data on MetS and brain MRI were available in 1,232 participants withmanifest arterial disease (age 58.6610.1 years; 37{\%}MetS). Volumes of brain tissue, ventricles, and white matter hyperintensities (WMH) were obtained by automated segmentation and expressed relative to intracranial volume. Infarcts were distinguished into lacunar and nonlacunar infarcts. RESULTS: The presence of MetS (n = 451) was associated with smaller brain tissue volume (B 20.72{\%} [95{\%} CI 20.97, 20.47]), even in the subgroup of patients without diabetes (B 20.42{\%} [95{\%} CI 20.71, 20.13]). MetS was not associated with an increased occurrence of WMH or cerebral infarcts. Impaired glucose metabolism, abdominal obesity, and elevated triglycerides were individual components associated with smaller brain volume. Obesity and hypertriglyceridemia remained associated with smaller brain volume when patients with diabetes were excluded. Hypertension was associated with an increased occurrence of WMH and infarcts. CONCLUSIONS: In patients with manifest arterial disease, presence of MetS is associated with smaller brain volume, even in patients without diabetes. Screening for MetS and treatment of its individual components, in particular, hyperglycemia, hypertriglyceridemia, and obesity, may prevent progression of cognitive aging in patients with MetS, even in a prediabetic stage.",
author = "Tiehuis, {Audrey M.} and {Van Der Graaf}, Yolanda and Mali, {Willem P T M} and Koen Vincken and Majon Muller and Geerlings, {Mirjam I.}",
year = "2014",
month = "1",
day = "1",
doi = "10.2337/dc14-0154",
language = "English",
volume = "37",
pages = "2515--2521",
journal = "Diabetes Care",
issn = "0149-5992",
publisher = "American Diabetes Association Inc.",
number = "9",

}

Metabolic syndrome, prediabetes, and brain abnormalities onmri in patients with manifest arterial disease : The smart-mr study. / Tiehuis, Audrey M.; Van Der Graaf, Yolanda; Mali, Willem P T M; Vincken, Koen; Muller, Majon; Geerlings, Mirjam I.

In: Diabetes Care, Vol. 37, No. 9, 01.01.2014, p. 2515-2521.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Metabolic syndrome, prediabetes, and brain abnormalities onmri in patients with manifest arterial disease

T2 - The smart-mr study

AU - Tiehuis, Audrey M.

AU - Van Der Graaf, Yolanda

AU - Mali, Willem P T M

AU - Vincken, Koen

AU - Muller, Majon

AU - Geerlings, Mirjam I.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - OBJECTIVE: Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors leading to atherosclerosis and diabetes. Diabetes is associated with both structural and functional abnormalities of the brain. MetS, even before diabetes is diagnosed, may also predispose to cerebral changes, probably through shared mechanisms. We examined the association of MetS with cerebral changes in patients with manifest arterial disease. RESEARCH DESIGN AND METHODS Cross-sectional data on MetS and brain MRI were available in 1,232 participants withmanifest arterial disease (age 58.6610.1 years; 37%MetS). Volumes of brain tissue, ventricles, and white matter hyperintensities (WMH) were obtained by automated segmentation and expressed relative to intracranial volume. Infarcts were distinguished into lacunar and nonlacunar infarcts. RESULTS: The presence of MetS (n = 451) was associated with smaller brain tissue volume (B 20.72% [95% CI 20.97, 20.47]), even in the subgroup of patients without diabetes (B 20.42% [95% CI 20.71, 20.13]). MetS was not associated with an increased occurrence of WMH or cerebral infarcts. Impaired glucose metabolism, abdominal obesity, and elevated triglycerides were individual components associated with smaller brain volume. Obesity and hypertriglyceridemia remained associated with smaller brain volume when patients with diabetes were excluded. Hypertension was associated with an increased occurrence of WMH and infarcts. CONCLUSIONS: In patients with manifest arterial disease, presence of MetS is associated with smaller brain volume, even in patients without diabetes. Screening for MetS and treatment of its individual components, in particular, hyperglycemia, hypertriglyceridemia, and obesity, may prevent progression of cognitive aging in patients with MetS, even in a prediabetic stage.

AB - OBJECTIVE: Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors leading to atherosclerosis and diabetes. Diabetes is associated with both structural and functional abnormalities of the brain. MetS, even before diabetes is diagnosed, may also predispose to cerebral changes, probably through shared mechanisms. We examined the association of MetS with cerebral changes in patients with manifest arterial disease. RESEARCH DESIGN AND METHODS Cross-sectional data on MetS and brain MRI were available in 1,232 participants withmanifest arterial disease (age 58.6610.1 years; 37%MetS). Volumes of brain tissue, ventricles, and white matter hyperintensities (WMH) were obtained by automated segmentation and expressed relative to intracranial volume. Infarcts were distinguished into lacunar and nonlacunar infarcts. RESULTS: The presence of MetS (n = 451) was associated with smaller brain tissue volume (B 20.72% [95% CI 20.97, 20.47]), even in the subgroup of patients without diabetes (B 20.42% [95% CI 20.71, 20.13]). MetS was not associated with an increased occurrence of WMH or cerebral infarcts. Impaired glucose metabolism, abdominal obesity, and elevated triglycerides were individual components associated with smaller brain volume. Obesity and hypertriglyceridemia remained associated with smaller brain volume when patients with diabetes were excluded. Hypertension was associated with an increased occurrence of WMH and infarcts. CONCLUSIONS: In patients with manifest arterial disease, presence of MetS is associated with smaller brain volume, even in patients without diabetes. Screening for MetS and treatment of its individual components, in particular, hyperglycemia, hypertriglyceridemia, and obesity, may prevent progression of cognitive aging in patients with MetS, even in a prediabetic stage.

UR - http://www.scopus.com/inward/record.url?scp=84906701270&partnerID=8YFLogxK

U2 - 10.2337/dc14-0154

DO - 10.2337/dc14-0154

M3 - Article

VL - 37

SP - 2515

EP - 2521

JO - Diabetes Care

JF - Diabetes Care

SN - 0149-5992

IS - 9

ER -